Sign in
Taking people in United StatesPhase 2

Compares two treatment combinations for a fast-growing blood cancer called DLBCL

Tests zilovertamab vedotin with standard chemotherapy in adults with newly diagnosed lymphoma.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Amarillo, Aurora, Austin, Baton Rouge, Boca Raton, Boston, Bozeman, Buffalo, Burbank, Burnsville, Chandler, Chapel Hill, Charleston, Charlotte, Chicago, Cincinnati, Cleveland, Dallas, Duarte, Edgewood, Elizabethtown, Glendale, Goodyear, Grand Junction, Hot Springs, Iowa City, Jacksonville, Knoxville, La Jolla, Lexington, Lincoln, Louisville, Madison, Manassas, Mayfield Heights, Miami Beach, Milwaukee, Mineola, Mobile, Monroe, Morristown, Murray, Nashville, New Orleans, New York, Newark, Omaha, Orange City, Palestine, Paramus, Peoria, Philadelphia, Portland, Post Falls, Richmond, San Antonio, Sellersville, Shreveport, St. George, Syracuse, Tyler, Vancouver, Walnut Creek, Washington D.C., Waukee, Westbury, Winston-Salem, and York, United StatesSee the 74 sitesAlso in 8 other countries, 80 sites
Trial code
Registry title
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Status
Recruiting
Phase
Phase 2
People taking part
594 people, planned
Started
11 Apr 2025
Expected to end
16 Dec 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zilovertamab vedotin
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Rituximab Biosimilar
  • Prednisone
  • Prednisolone
  • Polatuzumab vedotin
  • Rescue Medication
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with GCB-type diffuse large B-cell lymphoma who have not had any treatment for it yet.

Age
18 years or older
Sex
All sexes can join.
Disease stage
GCB subtype of diffuse large B-cell lymphoma (DLBCL), confirmed by a biopsy, with a positive PET scan at screening (4 to 5 on the Lugano 5-point scale).
Earlier treatment
No earlier treatment for DLBCL.
Biomarker or test result
GCB (germinal center B-cell) subtype on biopsy. People with HIV, hepatitis B or hepatitis C can join only if the infection is controlled or the virus cannot be detected.

Main reasons for not taking part

  • Lymphoma that changed from a slow-growing type into DLBCL
  • Primary mediastinal B-cell lymphoma or Grey zone lymphoma
  • Ann Arbor Stage I DLBCL
  • Active lymphoma in the central nervous system
  • History of stem cell or solid organ transplant

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues
  • Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
  • Has received no prior treatment for their DLBCL
  • Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Who cannot take part

  • Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma
  • Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
  • Has ongoing corticosteroid therapy
  • Has a history of transformation of indolent disease to DLBCL
  • Has a demyelinating form of Charcot-Marie-Tooth disease
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has active autoimmune disease that has required systemic treatment in the past 2 years
  • Has active infection requiring systemic therapy
  • Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection
  • Has history of stem cell/solid organ transplant
  • The main exclusion criteria include but are not limited to the following:
  • Has Ann Arbor Stage I DLBCL
  • Has clinically significant pericardial or pleural effusion
  • Has ongoing Grade >1 peripheral neuropathy
  • Known active central nervous system (CNS) lymphoma

Where in United States

Also in 8 other countries, 80 sites

  • Texas Oncology - West Texas (Site 8008)Amarillo, United StatesContact: Study CoordinatorTaking people
  • Rocky Mountain Cancer Centers (RMCC) (Site 8001)Aurora, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - Central/South Texas (Site 8006)Austin, United StatesContact: Study CoordinatorTaking people
  • Our Lady of the Lake Physician Group-Medical Oncology (Site 0180)Baton Rouge, United StatesContact: Study CoordinatorTaking people
  • Boca Raton Regional Hospital-Lynn Cancer Institute (Site 0130)Boca Raton, United StatesContact: Study CoordinatorTaking people
  • Beth Israel Deaconess Medical Center (Site 0161)Boston, United StatesContact: Study CoordinatorTaking people
  • Dana Farber Cancer Institute (Site 0111)Boston, United StatesContact: Study CoordinatorTaking people
  • Bozeman Health Deaconess Hospital (Site 0183)Bozeman, United StatesContact: Study CoordinatorTaking people
  • Roswell Park Cancer Institute (Site 0192)Buffalo, United StatesContact: Study CoordinatorTaking people
  • Erie County Medical Center (Site 0175)Buffalo, United StatesContact: Toll Free NumberNo longer taking part
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center (Site 0135)Burbank, United StatesContact: Study CoordinatorTaking people
  • Minnesota Oncology Hematology (MNO) (Site 8004)Burnsville, United StatesContact: Toll Free NumberNo longer taking part
  • Ironwood Cancer & Research Centers (Site 0204)Chandler, United StatesContact: Study CoordinatorTaking people
  • University of North Carolina Medical Center (Site 0136)Chapel Hill, United StatesContact: Study CoordinatorTaking people
  • Medical University of South Carolina (Site 0153)Charleston, United StatesContact: Study CoordinatorTaking people
  • Novant Health Presbyterian Medical Center (Site 0177)Charlotte, United StatesContact: Study CoordinatorTaking people
  • University of Chicago Medical Center (Site 0126)Chicago, United StatesContact: Study CoordinatorTaking people
  • University of Cincinnati Medical Center (Site 0156)Cincinnati, United StatesContact: Study CoordinatorTaking people
  • Cleveland Clinic Main (Site 0101)Cleveland, United StatesContact: Study CoordinatorTaking people
  • Fairview Hospital-Moll Cancer Center (Site 0198)Cleveland, United StatesContact: Study CoordinatorTaking people
  • University Hospitals of Cleveland (Site 0155)Cleveland, United StatesContact: Study CoordinatorTaking people
  • UT Southwestern Medical Center (Site 0190)Dallas, United StatesContact: Study CoordinatorTaking people
  • City of Hope Comprehensive Cancer Center (Site 0191)Duarte, United StatesContact: Study CoordinatorTaking people
  • Saint Elizabeth Medical Center Edgewood (Site 0141)Edgewood, United StatesContact: Study CoordinatorTaking people
  • Baptist Health Hardin (Site 0154)Elizabethtown, United StatesContact: Study CoordinatorTaking people
  • Palo Verde Cancer Specialists (Site 0105)Glendale, United StatesContact: Study CoordinatorTaking people
  • City of Hope - Phoenix (Site 0202)Goodyear, United StatesContact: Study CoordinatorTaking people
  • Colorado West Healthcare System-Grand Valley Oncology (Site 0165)Grand Junction, United StatesContact: Study CoordinatorTaking people
  • Genesis Cancer and Blood Institute (Site 0193)Hot Springs, United StatesContact: Study CoordinatorTaking people
  • University of Iowa-Holden Comprehensive Cancer Center (Site 0139)Iowa City, United StatesContact: Study CoordinatorTaking people
  • Baptist MD Anderson Cancer Center (Site 0176)Jacksonville, United StatesContact: Study CoordinatorTaking people
  • Tennessee Cancer Specialists (Site 7004)Knoxville, United StatesContact: Study CoordinatorTaking people
  • Moores Cancer Center (Site 0187)La Jolla, United StatesContact: Study CoordinatorTaking people
  • Baptist Health Lexington (Site 0127)Lexington, United StatesContact: Study CoordinatorTaking people
  • NHO Revive Research Institute, LLC (Site 0121)Lincoln, United StatesContact: Study CoordinatorTaking people
  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews (Site 0185)Louisville, United StatesContact: Study CoordinatorTaking people
  • SSM Health Dean Medical Group (Site 0106)Madison, United StatesContact: Study CoordinatorTaking people
  • Virginia Cancer Specialists, PC (Site 8003)Manassas, United StatesContact: Study CoordinatorTaking people
  • Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center (Site 0199)Mayfield Heights, United StatesContact: Study CoordinatorTaking people
  • Mount Sinai Braman Comprehensive Cancer Center (Site 0140)Miami Beach, United StatesContact: Study CoordinatorTaking people
  • Medical College of Wisconsin (Site 0103)Milwaukee, United StatesContact: Study CoordinatorTaking people
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island (Site 0208)Mineola, United StatesContact: Study CoordinatorTaking people
  • Infirmary Cancer Care (Site 0157)Mobile, United StatesContact: Study CoordinatorTaking people
  • Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic (Site 0209)Monroe, United StatesContact: Study CoordinatorTaking people
  • Atlantic Health Morristown Medical Center (Site 0163)Morristown, United StatesContact: Study CoordinatorTaking people
  • Intermountain Medical Center (Site 0182)Murray, United StatesContact: Study CoordinatorTaking people
  • SCRI Oncology Partners (Site 7002)Nashville, United StatesContact: Study CoordinatorTaking people
  • Ochsner Clinic Foundation (Site 0189)New Orleans, United StatesContact: Study CoordinatorTaking people
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone (Site 0108)New York, United StatesContact: Study CoordinatorTaking people
  • Medical Oncology Hematology Consultants (MOHC) (Site 8007)Newark, United StatesContact: Study CoordinatorTaking people
  • University Of Nebraska Medical Center (Site 0110)Omaha, United StatesContact: Study CoordinatorTaking people
  • Mid Florida Hematology and Oncology Center (Site 0152)Orange City, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - Northeast Texas (Site 8002)Palestine, United StatesContact: Study CoordinatorTaking people
  • Valley Health Systems - Ridgewood Campus (Site 0125)Paramus, United StatesContact: Study CoordinatorTaking people
  • Illinois Cancer Care (Site 7005)Peoria, United StatesContact: Study CoordinatorTaking people
  • Abramson Cancer Center and Perelman Center for Advanced Medicine (Site 0131)Philadelphia, United StatesContact: Study CoordinatorTaking people
  • Temple University Hospital (Site 0133)Philadelphia, United StatesContact: Study CoordinatorTaking people
  • Providence Oncology and Hematology Clinic Westside (Site 0179)Portland, United StatesContact: Study CoordinatorTaking people
  • Providence Portland Medical Center (Site 0120)Portland, United StatesContact: Study CoordinatorTaking people
  • Beacon Cancer Care (Site 0142)Post Falls, United StatesContact: Study CoordinatorTaking people
  • VCU Health Adult Outpatient Pavillion (Site 0138)Richmond, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - San Antonio (Site 8009)San Antonio, United StatesContact: Study CoordinatorTaking people
  • Alliance Cancer Specialists (ACS) (Site 8010)Sellersville, United StatesContact: Study CoordinatorTaking people
  • Louisiana State University Health Sciences Shreveport (Site 0195)Shreveport, United StatesContact: Study CoordinatorTaking people
  • Intermountain Healthcare - St. George (Site 0203)St. George, United StatesContact: Study CoordinatorTaking people
  • SUNY Upstate Cancer Center (Site 0178)Syracuse, United StatesContact: Study CoordinatorTaking people
  • The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center (Site 0145)Tyler, United StatesContact: Toll Free NumberNo longer taking part
  • Northwest Cancer Specialists (Compass Oncology) (Site 8000)Vancouver, United StatesContact: Study CoordinatorTaking people
  • Bass Medical Group (Site 0123)Walnut Creek, United StatesContact: Study CoordinatorTaking people
  • Georgetown University Medical Center (Site 0117)Washington D.C., United StatesContact: Study CoordinatorTaking people
  • Mission Blood & Cancer Care (Site 0114)Waukee, United StatesContact: Study CoordinatorTaking people
  • Optum Medical Care, PC (Site 0122)Westbury, United StatesContact: Study CoordinatorTaking people
  • Novant Health Forsyth Medical Center (Site 0206)Winston-Salem, United StatesContact: Study CoordinatorTaking people
  • Cancer Care Associates Of York (Site 0174)York, United StatesContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.

Read full original descriptionShow less

The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

The 2 groups in the trial

  • Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP)Treatment being tested

    Participants will receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 6 cycles (up to approximately 4 months) plus 2 additional cycles of rituximab or biosimilar for participants with high risk DLBCL. Participants will also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 3-week cycle for up to 6 cycles (up to approximately 4 months).

    Treatment: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, and Rescue Medication

  • Polatuzumab vedotin + R-CHPExisting treatment, for comparison

    Participants will receive a dose of polatuzumab vedotin (1.8 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by IV infusion on Day 1 of each 3-week cycle for up to 6 cycles (up to approximately 4 months) plus 2 additional cycles of rituximab or biosimilar for participants with high risk DLBCL. Participants will also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 3-week cycle for up to 6 cycles (up to approximately 4 months).

    Treatment: Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Polatuzumab vedotin, and Rescue Medication

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
Plain-language title
Compares two treatment combinations for a fast-growing blood cancer called DLBCLGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026